For example, instances of mutated EGFR accompanied by ligand amplification have been discerned in breast cancer, colorectal cancer, cutaneous squamous cell carcinoma, and non-small cell lung cancer (NSCLC) [30–34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.